Characteristics of CMV-seropositive recipients undergoing UCBT (n = 72)
| Characteristic . | Intensive strategy, n = 43, n (%) . | Standard strategy, n = 29, n (%) . | P . |
|---|---|---|---|
| Median age, y (IQR) | 31.7 (16-57) | 21.4 (10.1-41.9) | .10 |
| Sex | .74 | ||
| Female | 22 (51) | 16 (55) | |
| Male | 21 (49) | 13 (45) | |
| No. of donors | .50 | ||
| 1 | 5 (12) | 5 (17) | |
| 2 | 38 (88) | 24 (83) | |
| HLA disparity* | .14 | ||
| 4/6 | 25 (58) | 15 (52) | |
| 5/6 | 14 (32) | 14 (48) | |
| 6/6 | 4 (10) | - | |
| Transplantation type | .98 | ||
| Myeloablative | 34 (79) | 23 (79) | |
| Nonmyeloablative | 9 (21) | 6 (21) | |
| Total nucleated dose (× 107/kg) | .82 | ||
| median (IQR) | 3.9 (3.1-5.1) | 4.2 (2.5-6.0) | |
| Diagnosis | .60 | ||
| Acute lymphoblastic leukemia | 12 (28) | 7 (24) | |
| Acute myeloid leukemia | 21 (49) | 17 (59) | |
| CML | 3 (7) | 3 (9) | |
| Other | 7 (16) | 2 (6) | |
| Disease risk† | .02 | ||
| Standard risk | 29 (67) | 26 (90) | |
| High risk | 14 (33) | 3 (10) |
| Characteristic . | Intensive strategy, n = 43, n (%) . | Standard strategy, n = 29, n (%) . | P . |
|---|---|---|---|
| Median age, y (IQR) | 31.7 (16-57) | 21.4 (10.1-41.9) | .10 |
| Sex | .74 | ||
| Female | 22 (51) | 16 (55) | |
| Male | 21 (49) | 13 (45) | |
| No. of donors | .50 | ||
| 1 | 5 (12) | 5 (17) | |
| 2 | 38 (88) | 24 (83) | |
| HLA disparity* | .14 | ||
| 4/6 | 25 (58) | 15 (52) | |
| 5/6 | 14 (32) | 14 (48) | |
| 6/6 | 4 (10) | - | |
| Transplantation type | .98 | ||
| Myeloablative | 34 (79) | 23 (79) | |
| Nonmyeloablative | 9 (21) | 6 (21) | |
| Total nucleated dose (× 107/kg) | .82 | ||
| median (IQR) | 3.9 (3.1-5.1) | 4.2 (2.5-6.0) | |
| Diagnosis | .60 | ||
| Acute lymphoblastic leukemia | 12 (28) | 7 (24) | |
| Acute myeloid leukemia | 21 (49) | 17 (59) | |
| CML | 3 (7) | 3 (9) | |
| Other | 7 (16) | 2 (6) | |
| Disease risk† | .02 | ||
| Standard risk | 29 (67) | 26 (90) | |
| High risk | 14 (33) | 3 (10) |
CML indicates chronic myelogenous leukemia; IQR, interquartile range; and UCBT, umbilical cord blood transplantation.
For recipients of 2 UCB units, the HLA matching reflects the worse matched of the 2 units.
Disease risk: standard refers to aplastic anemia, chronic myeloid leukemia in chronic phase, myelodysplastic syndromes without excess blasts, and leukemia and lymphoma in remission. High refers to all other hematologic malignancies.25 The Fisher exact test and Wilcoxon rank-sum analyses were used to calculate categorical and continuous variables, respectively.